Associated Papers
Organoid-based precision cancer modeling: New frontier in lung cancer research.
Terai H et al.
Cell Reports, 2025
Autoregulation of the MET receptor tyrosine kinase by its intracellular juxtamembrane domain.
Linossi EM et al.
The Biochemical Journal, 2025
MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.
Hu J et al.
Molecular Oncology, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.
Febres-Aldana CA et al.
Cancer Discovery, 2025
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements.
Nakazawa S et al.
Cancer Discovery, 2025
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR et al.
Clinical and Translational Medicine, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.
Cheng W et al.
The Oncologist, 2025
Advances in the diagnosis and treatment of MET-variant digestive tract tumors.
Zhang C et al.
World Journal of Gastrointestinal Oncology, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
Marks JA et al.
Lung Cancer (amsterdam, Netherlands), 2024
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D.
Zheng Q et al.
Nature Chemical Biology, 2024
Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X et al.
Journal of Cancer Research and Clinical Oncology, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Wu YL et al.
The Lancet. Oncology, 2024
Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study.
Zhou H et al.
Discover Oncology, 2024
Recording and classifying MET receptor mutations in cancers.
Guérin C et al.
Elife, 2024
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.
Yuan P et al.
Therapeutic Advances in Medical Oncology, 2024
Joint DNA-RNA-based NGS for diagnosis and treatment of a rare CD47-MET fusion lung adenocarcinoma which was immunoresistant and savoltinib-sensitive: a case report.
Wang R et al.
Frontiers in Immunology, 2024
Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
Schmalz L et al.
Lung Cancer (amsterdam, Netherlands), 2023
Biophysical and structural characterization of the impacts of MET phosphorylation on tepotinib binding.
Grädler U et al.
The Journal of Biological Chemistry, 2023
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.
Jóri B et al.
Current Oncology (toronto, Ont.), 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.
Michaelides IN et al.
Journal of Medicinal Chemistry, 2023
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R et al.
Cancers, 2023
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Albers J et al.
Molecular Cancer Therapeutics, 2023
[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2023
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C et al.
Cancers, 2023
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.
Zhou J et al.
Signal Transduction and Targeted Therapy, 2023
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
Kang J et al.
Lung Cancer (amsterdam, Netherlands), 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
Wu H et al.
Bmc Cancer, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease.
Blaquier JB et al.
Drugs in Context, 2022
Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting.
Ai X et al.
Therapeutic Advances in Medical Oncology, 2022
Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models.
Xu Y et al.
Frontiers in Oncology, 2022
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study.
Yu Y et al.
Therapeutic Advances in Medical Oncology, 2022
Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
Kawahata W et al.
Journal of Medicinal Chemistry, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
Dagogo-Jack I et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
Kim CG et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Lee M et al.
Expert Opinion on Therapeutic Targets, 2021
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
Liu L et al.
Frontiers in Oncology, 2021
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation.
Cai B et al.
Frontiers in Oncology, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X et al.
Jco Precision Oncology, 2021